NYLI MacKay Muni Insured ETF (ARCA: MMIN)

Latest news for NYLI MacKay Muni Insured ETF (ARCA:MMIN)

IQ MacKay Shields Municipal Insured ETF ETF

The Fund, under normal circumstances, invests at least 80 percent of its assets (net assets plus borrowings for investment purposes) in debt securities whose interest is, in the opinion of bond counsel for the issuer at the time of issuance, exempt from federal Income tax (Municipal Bonds); and debt securities covered by an insurance policy guaranteeing the payment of principal and interest.

Dreyfus Tax Exempt Cash Management

IQ MacKay Municipal Insured ETF

NYLI MacKay Muni Insured ETF

U.S. stock futures climbed on Thursday in premarket hours after the indices declined in the previous session following a <a href="https://www.benzinga.com/news/econ-s/24/12/42561549/fed-slashes-interest-rates-by-0-25-as-predicted-december-dot-plot-flags-only-2-potential-cuts-in-2025">hawkish cut</a> from the Federal Reserve. The futures of all four major indices were trading higher.
The 10-year and two-year Treasury notes yielded 4.54% and 4.32%, respectively.
On Wednesday, the Federal Reserve did reduce interest rates by 0.25% to a range of 4.25%-4.5%, as expected. However, the revised economic projections indicate only two possible rate cuts in 2025—down from the four predicted in September and fewer than the three that markets had anticipated before the meeting.
The probability of having no change in the interest rates for the upcoming Jan. 31, 2025 decision was at 91.4%, <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">according</a> to CME Group&#8217;s FedWatch tool.
GDP revisions slated to be released later today will reveal whether the economy maintained the previously estimated 2.8% growth rate for the third quarter.
Investors will receive another critical economic data point on Friday with the release of the November personal consumption expenditures (PCE) inflation index. This release follows other inflation indicators that suggest price increases accelerated in November.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.28%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.40%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.37%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.39%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Thursday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 0.52% to $589.35 and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.48% to $518.94, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Cues From The Last Session
U.S. stocks closed lower on Wednesday, with the <a href="https://www.benzinga.com/news/earnings/24/12/42569953/dow-dips-over-1100-points-falling-for-10th-session-as-powell-adopts-hawkish-stance-greed-index-moves-to-fear-zone">Dow Jones dropping for the tenth consecutive session</a>, falling by more than 1,100 points.
On the economic front, the U.S. posted a current account deficit of $310.9 billion in the third quarter, up from a revised deficit of $275.0 billion in the previous quarter and exceeding market expectations of a $284 billion gap. Meanwhile, U.S. housing starts declined by 1.8%, reaching an annualized rate of 1.289 million units in November, down from 1.312 million in October.
All sectors of the S&amp;P 500 ended the day in the red, with consumer discretionary, real estate, and communication services stocks seeing the largest losses.
&#8220;It&#8217;s been a very mild year with just 17 declines of 1% or more,&#8221; said Charlie Bilello, chief market strategist at Creative Planning Investor.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The S&amp;P 500 fell 2.95% today, the worst day for stocks since August 5 (Nikkei black Monday crash). Overall, it&#39;s been a very mild year with just 17 declines of 1% or more (vs. 29 in the average year). History of large down days since 1928&#8230; <a href="https://twitter.com/search?q=%24SPX&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SPX</a><a href="https://t.co/l5IYmkf6Ih">https://t.co/l5IYmkf6Ih</a> <a href="https://t.co/XSAGBsgiIY">pic.twitter.com/XSAGBsgiIY</a>
&mdash; Charlie Bilello (@charliebilello) <a href="https://twitter.com/charliebilello/status/1869527952851116382?ref_src=twsrc%5Etfw">December 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-3.56%</td>
<td>19,392.69</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-2.95%</td>
<td>5,872.16</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-2.58%</td>
<td>42,326.87</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-4.39%</td>
<td>2,231.51</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
Talking about her 2025 projections after the Fed&#8217;s rate cut, Julia Khandoshko, the CEO of Mind Money in a conversation with <a href="https://www.benzinga.com">Benzinga</a> said, &#8220;In 2025, investors should focus on three key strategies: monitoring the impact of political and economic changes on markets, investing in promising sectors such as AI and biotechnology without excessive dependence on technology, and actively diversifying the portfolio with traditional industries and new opportunities in emerging markets.&#8221;
Chris Zaccarelli, chief investment officer for Northlight Asset Management, said that markets are forward-looking and reacted to the Fed&#8217;s 2025 projection and not the quarter-point cut that it delivered.
&#8220;Santa came early and dropped a 25-bps rate cut in the market&#8217;s stocking but accompanied it with a note saying that there would be coal next year,&#8221; Zaccarelli said.
Jeremy Siegel, professor emeritus at the University of Pennsylvania's Wharton School, described the stock market's recent downturn as a "healthy" reaction to the Federal Reserve's cautious approach to future interest rate cuts.
&#8220;The market was overly optimistic…so I am not surprised at the sell-off,&#8221; he said.
He suggested that the Fed might reduce rates only once or twice next year, with the possibility of no cuts at all due to inflation concerns. Siegel also mentioned potential tariffs from President-elect Donald Trump could impact inflation, though he believes the actual tariffs may not be as significant as feared.
Bill Adams, chief economist for Comerica Bank, said the Fed is reacting to the incoming Trump administration&#8217;s policies, which it sees as most likely to boost growth and inflation, as well as tighten the job market.
Trump does not have much control over the pace of rate cuts in the near term, Adams said, but &#8220;that could change in 2026 if President-elect Trump gets the Senate to confirm a new Fed chair who is more sympathetic to his policy goals.&#8221;
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures" target="_blank" rel="noreferrer noopener">How To Trade Futures</a>
Upcoming Economic Data
Important data is slated to be released in the rest of the week that will help investors determine the future course of action.
<ul>
<li>On Thursday, the data for initial jobless claims till Dec. 14, GDP&#8217;s second revision for the third quarter, and Philadelphia Fed manufacturing survey data for December will be released at 8:30 a.m., ET.</li>
<li>Existing home sales data and U.S. leading economic indicators for November will be announced at 10:00 a.m., ET.</li>
<li>On Friday, personal income and spending data along with core and headline PCE index data for November will be released at 8:30 a.m., ET.</li>
<li>Consumer sentiment data for December will be released at 10:00 a.m., ET.</li>
<li>Carnival Corporation and Winnebago Industries will report earnings.</li>
</ul>
Stocks In Focus:
<ul>
<li>Accenture Plc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) was up 3.56% ahead of its Q1 earnings call scheduled before the opening bell. Wall Street expects quarterly earnings at $3.40 per share on revenue of $17.12 billion.</li>
<li>Micron Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) was down 15.52% after it posted better-than-expected earnings but sales missed expectations in the first quarter.</li>
<li>Nike Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) was just up 0.4% in premarket a analysts expect it to post quarterly earnings at 64 cents per share on revenue of $12.13 billion after the closing bell.</li>
<li>Lennar Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) was 8.85% lower in premarket trading after it reported worse-than-expected financial results for the fourth quarter.</li>
<li>Sangamo Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) was up 22.55% after it inked an agreement with Astellas Pharma allowing the latter to leverage Sangamo&#8217;s novel proprietary neurotropic adeno-associated virus capsid. Sangamo will receive a $20 million upfront license fee and is eligible to earn up to $1.3 billion in additional licensed target fees.</li>
<li>KULR Technology Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NYSE">KULR</a>) was up 27.88% after it announced plans to launch the KULR ONE Space battery via launch integrator Exolaunch on a SpaceX rideshare mission scheduled for 2026.</li>
<li>Mesoblast Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) rose 42.61% in pre-market trading after Mesoblast's RYONCIL became the first FDA-approved mesenchymal stromal cell therapy in the U.S.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures were lower in the early New York session by 0.94% to hover around $69.92 per barrel.
The gold spot index fell by 0.82% to $2,631.59 per ounce. The Dollar Index was down 0.12% to 107.893 level.
Asian markets declined on Thursday, as Hong Kong&#8217;s Hang Seng, South Korea&#8217;s Kospi, Japan&#8217;s Nikkei 225, India&#8217;s S&amp;P BSE Sensex, and Australia&#8217;s ASX 200 index fell, while China&#8217;s CSI 300 index ended marginally higher.
Most European markets were also trading lower.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42571821/why-sangamo-therapeutics-shares-are-trading-higher-by-around-20-here-are-20-stocks-moving-premarket">Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket</a></li>
</ul>
Photo courtesy: Wikimedia

Equities

Market Summary

News

Futures

Economics

Federal Reserve

Pre-Market Outlook

Markets

Movers

Trading Ideas

KULR

MESO

SGMO

US Stocks Likely To Open Higher After Plunging On Powell's Hawkish Comments: Analyst Calls It A 'Healthy' Reaction From An 'Overly Optimistic' Market

Results demonstrate that inhaled AP-PA02 provides a durable reduction of Pseudomonas aeruginosa in the lung, with a favorable safety and tolerability profile

Biotech

Health Care

General

ARMP

Armata Pharmaceuticals Announced Topline Results From Its Phase 2 Tailwind Trial Of AP-PA02 For Chronic Pulmonary Pseudomonas Aeruginosa Infections In Non-cystic Fibrosis Bronchiectasis Patients

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Sell and maintains $75 price target.

Price Target

Reiteration

Analyst Ratings

SRPT

HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $75 Price Target

Citigroup analyst James Hardiman initiates coverage on Viking Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIK#NYSE">VIK</a>) with a Buy rating and announces Price Target of $54.

Initiation

Citigroup Initiates Coverage On Viking Holdings with Buy Rating, Announces Price Target of $54

Contracts

MASS

908 Devices And Getinge Announce Their Collaboration To Integrate Getinge's Bioreactors With 908 Devices' MAVEN For Automated Control Of Glucose And Lactate Levels In Cell Cultures

The investment consists of the purchase of 12.5 million shares of Verde's Class A common stock at a purchase price of $4.00 per share. Closing of the investment is anticipated to occur during Q1 2025, subject to satisfaction of customary closing conditions. Upon closing, the investment would represent the second investment by Cottonmouth in Verde over the past two years, for a total investment of $70 million, making Cottonmouth the second largest shareholder of Verde.&nbsp;

Financing

Commodities

FANG

VGAS

Verde Clean Fuels Entered Into A Stock Purchase Agreement With Cottonmouth Ventures, A Wholly-Owned Subsidiary Of Diamondback Energy, For A $50M Equity Investment

In a bid to attract budget-savvy travelers, Frontier Airlines by Frontier Group Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULCC#NASDAQ">ULCC</a>) has announced the launch of its &#8220;GoWild!&#8221; pass, offering unlimited flights for a year at an introductory price of $299. This offer, which targets spontaneous adventurers, is available to the first 5,000 customers who sign up before the pre-sale ends on December 18.
What Happened: Frontier Airlines is launching a new offer aimed at budget-conscious travelers. The airline&#8217;s &#8220;GoWild!&#8221; pass, priced at $299 annually, provides unlimited flights for a limited time, CNBC <a href="https://www.cnbc.com/2024/12/18/frontier-airlines-all-you-can-fly-pass.html">reported</a> on Thursday 
The &#8220;GoWild!&#8221; pass is designed for spontaneous travelers and those seeking endless adventures, according to Bobby Schroeter, Chief Commercial Officer of Frontier Airlines. The offer is limited to the first 5,000 customers who sign up before the pre-sale ends on Dec. 18 at 11:59 p.m. MST. After this period, the price will rise to $499.
See Also: <a href="https://www.benzinga.com/tech/24/12/42525257/analyst-hikes-teslas-price-target-to-515-musk-expresses-hope-for-stock-to-touch-69042?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Hopes TSLA Stock Will Reach $690 As Analysts Raise Price Target Despite Technical Indicators Flashing Warning Signals</a>
Eligibility for the pass requires users to be at least 18 years old, U.S. residents,&nbsp;and members of Frontier Miles,&nbsp;the airline&#8217;s loyalty program. New customers will be enrolled automatically upon purchase. Pass holders can book flights for a penny, but must cover taxes and fees.
Restrictions include no seat reservations and no carry-on or checked baggage. Domestic flights can be booked a day before departure, while international flights require a 10-day advance booking. The pass is valid from May 1, 2025, to April 30, 2026, excluding holiday and peak travel dates.
Why It Matters: The introduction of the &#8220;GoWild!&#8221; pass by Frontier Airlines comes amid a growing trend among budget airlines to offer unlimited flight passes. In August, European budget airline Wizz Air Holdings launched a similar initiative <a href="https://www.benzinga.com/news/24/08/40387905/this-least-punctual-airline-is-now-offering-a-550-all-you-can-fly-annual-pass-with-unlimited-flights">with a $550 annual pass</a>, allowing unlimited flights to international destinations. 
This pass, available initially at a discounted rate, aimed to attract more customers despite the airline&#8217;s reputation for punctuality issues. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/12/42545829/mark-cuban-expresses-sympathy-for-hawk-tuah-girl-amid-meme-coin-controversy-wasnt-something-she-fully-understood?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Mark Cuban Expresses Sympathy For &#8216;Hawk Tuah&#8217; Girl Amid Meme Coin Controversy: &#8216;Wasn&#8217;t Something She Fully Understood&#8217;</a></li>
</ul>
Image via Shutterstock

Travel

ULCC

This Budget US Airline Is Offering A 'GoWild' Pass: Catch Unlimited Flights For A Year At $299

Needham analyst Scott Berg reiterates UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) from Hold to Hold.

PATH

Needham Reiterates Hold on UiPathto Hold

Jefferies analyst Joseph Gallo upgrades SentinelOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) from Hold to Buy and raises the price target from $27 to $30.

Upgrades

Jefferies Upgrades SentinelOne to Buy, Raises Price Target to $30

BP1001-A downregulates growth factor receptor-bound protein 2 (Grb2) expression to increase insulin sensitivity and helps lower blood glucose level in Type 2 diabetes patients. Scientific evidence suggeststhat by downregulating Grb2 expression, BP1001-A&nbsp;could help lower blood glucose level by affecting insulin signaling. Bio-Path conducted preclinical studies that confirmed the effectiveness of BP1001-A in affecting insulin signaling and its potential efficacy as a therapeutic treatment for obese patients who have Type 2 diabetes.&nbsp;&nbsp; The study results showed:
<ul>
<li>BP1001-A reduced Grb2 protein expression in myoblast cells</li>
<li>BP1001-A increased the levels of phosphorylated AKT and phosphorylated FOXO-1 in myoblast and hepatoma cells in the presence of insulin</li>
</ul>
These initial data confirmed that by downregulating Grb2 expression, BP1001-A could enhance insulin-induced metabolic events by affecting the insulin/phosphoinositol-3 kinase (PI3K)/AKT pathway and increase insulin sensitivity.&nbsp;

BPTH

Bio-Path Reported That Results From Preclinical Studies Of BP1001-A For Obesity Demonstrated Enhanced Insulin Sensitivity, Confirming BP1001-A As A Potential Treatment For Obesity And Related Metabolic Diseases In Type 2 Diabetes Patients

WIIM

Bio-Path Holdings shares are trading higher after the company announced preclinical testing of BP1001-A as a potential treatment for obesity in Type 2 diabetes patients by enhancing insulin sensitivity.

MNMD

MindMed To Be Added To The Nasdaq Biotechnology Index, Effective At Market Open On December 23, 2024

VRAR

The Glimpse Group shares are trading higher after its subsidiary, Brightline Interactive, announced a six-figure contract with the U.S. Navy for an immersive simulator.

ACET

Adicet Bio Says First Patient Dosed In The Phase 1 Clinical Trial Evaluating ADI-270 In Patients With Metastatic/Advanced ccRCC

The Glimpse Group's Subsidiary Company Brightline Interactive Has Entered Into An Initial Six Figure Dollar Contract With The U.S. Navy For An Immersive Simulator, To Be Delivered In The First Half Of 2025

Jefferies analyst Michael Yee downgrades ALX Oncology Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) from Buy to Hold and lowers the price target from $12 to $2.

Downgrades

ALXO

Jefferies Downgrades ALX Oncology Holdings to Hold, Lowers Price Target to $2

Fiscal 2025 Expectations
•Organic ASV is expected to grow in the range of $90 million to $140 million during fiscal 2025.
•GAAP revenues are expected to be in the range of $2,285 million to $2,305 million.
•GAAP operating margin is expected to be in the range of 32.5% to 33.5%.
•Adjusted operating margin is expected to be in the range of 36.0% to 37.0%.
•FactSet's annual effective tax rate is expected to be in the range of 17% to 18%.
•GAAP diluted EPS is expected to be in the range of $15.10 to $15.70.
•Adjusted diluted EPS is expected to be in the range of $16.80 to $17.40.

Earnings

Guidance

FactSet Reaffirms FY25 Guidance: Sees Revenues Of $2.285B - $2.305B Vs. $2.301B Est., And Adjusted EPS Of $16.80 - $17.40 Vs. $17.17 Est.

HC Wainwright &amp; Co. analyst Sean Lee reiterates Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Buy and maintains $7 price target.

VSTM

HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $7 Price Target

LASE

Laser Photonics Receives Dual Order From Oil Refiner Phillips 66 For CleanTech And MarkStar Laser Systems; No Terms Disclosed

In addition to the Fast Track designation announced today for Waldenstrom's macroglobulinemia, NX-5948 previously received Fast Track designation in January 2024 for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) after at least two lines of therapy, including a BTK inhibitor and a B-cell lymphoma 2 (BCL2) inhibitor.

NRIX

Nurix Says FDA Granted Fast Track Designation For NX-5948 For Treatment Of Adult Patients With Relapsed Or Refractory Waldenstrom's Macroglobulinemia After At Least Two Lines Of Therapy

Columbia Threadneedle Fixed-Income Monitor: October 2024

Q4 2024 Fixed Income Perspectives

Federal Government Efficiency Commission Trickle-Down To State And Local Municipalities

Comments

NYLI MacKay Muni Insured ETF

News

Latest news for NYLI MacKay Muni Insured ETF (ARCA:MMIN)

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga